272 related articles for article (PubMed ID: 24227007)
1. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry.
Peña L; Gama A; Goldschmidt MH; Abadie J; Benazzi C; Castagnaro M; Díez L; Gärtner F; Hellmén E; Kiupel M; Millán Y; Miller MA; Nguyen F; Poli A; Sarli G; Zappulli V; de las Mulas JM
Vet Pathol; 2014 Jan; 51(1):127-45. PubMed ID: 24227007
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs.
Mainenti M; Rasotto R; Carnier P; Zappulli V
Vet J; 2014 Oct; 202(1):62-8. PubMed ID: 24980810
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
4. Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
Im KS; Kim IH; Kim NH; Lim HY; Kim JH; Sur JH
Vet J; 2013 Mar; 195(3):366-72. PubMed ID: 22901454
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
[TBL] [Abstract][Full Text] [Related]
6. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
Kim NH; Lim HY; Im KS; Kim JH; Sur JH
J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
[TBL] [Abstract][Full Text] [Related]
7. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
8. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
10. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
11. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
13. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
[TBL] [Abstract][Full Text] [Related]
15. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
[TBL] [Abstract][Full Text] [Related]
16. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
19. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours.
Maniscalco L; Iussich S; de Las Mulas JM; Millán Y; Biolatti B; Sasaki N; Nakagawa T; De Maria R
Vet J; 2012 Jan; 191(1):65-71. PubMed ID: 21282070
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours.
Pastor N; Ezquerra LJ; Santella M; Caballé NC; Tarazona R; Durán ME
Vet Comp Oncol; 2020 Dec; 18(4):753-762. PubMed ID: 32336005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
